该团队计划尽快使用该模型来研究他们是否能使用移植的胚胎和诱导的多向干细胞而不是成熟的肝细胞来产生器官。
The team plans to soon use the model to see whether they can generate organs using transplanted embryonic and induced pluripotent stem cells rather than mature liver cells.
我们的研究使的研究人肝发育的潜在分子机制变得容易，并且形成肝细胞移植和药物实验的基础。
Our studies should facilitate searching the molecular mechanisms underlying human liver development, and form the basis for hepatocyte transplantation and drug tests.
结论：这里我们鉴别了在等待肝移植的HCV -肝癌患者中，和肝细胞癌进展相关的基因。
CONCLUSIONS: Here, we have identified genes associated with HCC progression in HCV-HCC patients awaiting LT transplantation.
结论肝移植术后血清醛缩酶、亮氨酸转肽酶和谷氨酸脱氢酶可作为新植入肝脏肝细胞损伤的有效指标，为临床治疗提供帮助。
Conclusion Serum ALD, LAP and GLDH levels are effective markers of hepatocellular damage after liver-transplantation and conducive to clinical therapy.
肝细胞微囊化有助于为肝细胞移植的推广应用提供大量的具有高度活性和良好功能的肝细胞。
Microencapsulated hepatocytes contribute to the promotion and application for liver cell transplantation, for which provide a large amount of high activity and good function of liver cells.
由于缺乏预测进展和复发的肿瘤标志物那些有可能被治疗的更高阶段的肝细胞癌的患者被拒绝用肝移植疗法。
Potentially curable higher-stage HCC patients are denied LT due to the lack of cancer markers that predict progression and recurrence.
由于缺乏预测进展和复发的肿瘤标志物那些有可能被治疗的更高阶段的肝细胞癌的患者被拒绝用肝移植疗法。
Potentially curable higher-stage HCC patients are denied LT due to the lack of cancer markers that predict progression and recurrence.
应用推荐